ArticleFrontiers in immunology2025

Using body composition to predict treatment-related adverse events and disease-free survival in patients with gastrointestinal stromal tumors treated with imatinib: a retrospective cohort study.

Tianhao Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.